ArticleJournal of obstetrics and gynaecology of India2024
Survival Trends Following Surgical Management in Carcinoma Vulva Patients During Covid 19 Pandemic: A Tertiary Care Hospital Study.
Article in Journal of obstetrics and gynaecology of India, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of the COVID-19 Pandemic on Tumor Stage and Pathohistological Parameters of Vulvar Cancer.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vulval cancers account for 0.25% of new cancer cases and 0.2% of new deaths of all sites worldwide making it an uncommon malignancy according to Global cancer Statistics 2020. Covid 19 for two years made the situation worse. Proper investigations, adjuvant therapy and follow-up for complications was a challenge. The present study is a prospective observational study on treatment outcome of Carcinoma Vulva at a tertiary care hospital during COVID-19 pandemic. Methods: Twenty patients of non-metastatic carcinoma vulva were recruited over 22 months of Covid 19 pandemic. Surgery was individualized as wide local excision or radical vulvectomy. Inguinal nodes were addressed as per location of tumour. All cases were followed 2 monthly with virtual/physical meetings till 18 months. Changes in accordance with ongoing COVID 19 pandemic were made in carcinoma vulva diagnostic tests, preoperative work up, intra operatively, post-op complication management and follow-up. Results: The mean age of the study participants was 59.85 ± 10.32 years. In the sample population analysed, menopause was experienced on average at the age of 49.47 ± 4.29 years. Thirty five percent (7) of patients had positive lymph nodes during surgery. All 3 patients who died had positive lymph nodes. Also, all three had no taken adjuvant treatment advised to them by the tumour board. Phased resumption of complex surgeries and adaptation to better PPEs helps in the staff acclimatization to the new normal of operating under constant threat of COVID. In our study, 85% patients were disease free at 18 months follow-up. This is similar to outcomes of carcinoma vulva cases in non-Covid times. There was no difference amongst re-exploration, morbidity and mortality rates for cancer surgeries in COVID and non-COVID years highlighting the fact that effective implementation of cancer surgery and peri operative care guidelines is crucial for good surgical outcomes. Conclusion: This study sheds light on good prognosis of carcinoma vulva with proper treatment and follow-up. Covid times were managed with virtual meets and talking with local practitioners. Screening programs, rural awareness camps and more studies are needed in this field. Supplementary Information: The online version contains supplementary material available at 10.1007/s13224-023-01935-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.